Using gnotobiotic mice to discover and validate therapeutically active microbiota to maintain mucosal homeostasis and treat intestinal inflammation

Q3 Pharmacology, Toxicology and Pharmaceutics

Drug Discovery Today: Disease Models Pub Date : 2018-06-01 DOI:10.1016/j.ddmod.2019.08.009

R. Balfour Sartor

引用次数: 1

Abstract

Studies in gnotobiotic mice have dramatically expanded our understanding of the functional importance of microbiota in the pathogenesis of chronic intestinal inflammation. This brief review describes several strategies by which gnotobiotic mice models can be used to efficiently discover and validate protective components from the resident microbiota for potential therapeutic applications. We provide highly targeted examples of studies that use each of the various strategies to illustrate effective approaches, discuss challenges to implementing these approaches and suggest future directions to accelerate this increasingly important line of research and improve the clinical applications of results.

查看原文本刊更多论文

利用益生小鼠发现并验证具有治疗活性的微生物群，以维持粘膜稳态和治疗肠道炎症

无菌小鼠的研究极大地扩展了我们对微生物群在慢性肠道炎症发病机制中的功能重要性的理解。这篇简短的综述描述了几种策略，通过这些策略，生物小鼠模型可以有效地发现和验证来自常驻微生物群的潜在治疗应用的保护成分。我们提供了高度针对性的研究实例，使用每种不同的策略来说明有效的方法，讨论实施这些方法的挑战，并建议未来的方向，以加速这一日益重要的研究方向，并改善结果的临床应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Discovery Today: Disease Models Pharmacology, Toxicology and Pharmaceutics-Drug Discovery

自引率

0.00%

发文量

期刊介绍： Drug Discovery Today: Disease Models discusses the non-human experimental models through which inference is drawn regarding the molecular aetiology and pathogenesis of human disease. It provides critical analysis and evaluation of which models can genuinely inform the research community about the direct process of human disease, those which may have value in basic toxicology, and those which are simply designed for effective expression and raw characterisation.